Given the high proportion of triple-negative breast cancer in BLBC and the common feature of BRCA1-defective breast cancer and BLBC, perhaps for the treatment modalities of CNC, we can attempt to use targeted therapy for BRCA1. This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.